Figure 8.

PI3K and ROCK inhibitor‐induced airway dilation in the presence and absence of IL‐13. hPCLS were incubated in the presence or absence of IL‐13 (100 ng·mL⁻¹, 18 h), precontracted to ~60–70% of baseline luminal area and relaxed to a dose response of LY294002, CAL‐101 or the β₂‐adrenoceptor agonist formoterol (10⁻¹¹–10⁻⁵ M). AUC was compared between control and IL‐13 treatment for each compound used to dilate the airways. Data are representative of n ≥ 4 donors, 5–44 slices per condition, with bars representing mean + SEM, with P ≤ 0.05 considered significant (ANOVA P = 0.01; two‐tailed t‐tests: control versus IL‐13 for formoterol P = 0.009, control versus IL‐13 for CAL‐101 P = n.s., control versus IL‐13 for LY294002 P = n.s.).